Focuses on developing treatments for serious infectious diseases.
Vir Biotechnology, Inc. is a leading immunology company operating in the commercial stage, dedicated to advancing therapeutic solutions for the treatment and prevention of serious infectious diseases. The company's robust pipeline includes innovative products targeting a spectrum of viral infections.
Among its key developments, Vir Biotechnology is advancing Sotrovimab (VIR-7832), a potent SARS-CoV-2-neutralizing monoclonal antibody marketed under the Xevudy brand. This treatment is designed to both treat and prevent COVID-19 infections, showcasing the company's commitment to combating global health challenges.
In addition to Sotrovimab, Vir Biotechnology is actively pursuing VIR-2218 and VIR-3434 for the treatment of hepatitis B virus, VIR-2482 for influenza A virus prevention, and VIR-1111 for human immunodeficiency virus prevention. These initiatives highlight the company's diverse portfolio aimed at addressing critical medical needs worldwide.
Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology has forged strategic partnerships and collaborations with prominent entities such as the Bill & Melinda Gates Foundation, National Institutes of Health, and several biopharmaceutical leaders. These alliances underscore Vir Biotechnology's commitment to leveraging cutting-edge science and collaborative innovation to accelerate the development and delivery of transformative therapies.